Further data on the safety of dual ICI therapy in patients with AILD is urgently needed, especially when the recent approval of combined immunotherapy with the CTLA-4 inhibitor tremelimumab and the PD-L1 inhibitor durvalumab for HCC is being considered. Here, CD274 is linked to hepatocellular carcinoma.